Economic Burden of Fatigue in Inflammatory Bowel Disease
Crohn's & Colitis 360 · 01.07.2023 · 5 (3)
DOI: 10.1093/crocol/otad020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Crohn's & Colitis 360, online erschienen am 20.04.2023. Verfasst von Ashwin N Ananthakrishnan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Massachusetts General Hospital and Harvard medical School, Boston, MA, USA. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This retrospective study gathered medical/pharmacy claims data on patients with inflammatory bowel disease (IBD) between January 01, 2000 and March 31, 2019 from the IBM MarketScan commercial claims database to assess the real-world impact of fatigue on healthcare costs in patients newly diagnosed with IBD.
Methods
Eligible participants were ≥18 years, newly diagnosed with IBD (≥2 separate claims), and had ≥12 months of continuous database enrollment before and after fatigue diagnosis. The date of fatigue diagnosis was the index date; participants were followed for 12 months post-index. Patients with (cases) or without (controls) fatigue were matched 1:1 by propensity score matching. Patients with evidence of prior IBD diagnosis/treatment, or those with a chronic disease other than IBD wherein fatigue is the primary symptom, were excluded. Healthcare resource utilization (HCRU), including hospitalizations, inpatient and outpatient visits, and associated costs were compared between cases and controls.
Results
Matched IBD cohorts (21 321 cases/21 321 controls) were identified (42% Crohn’s disease [CD] and 58% ulcerative colitis [UC]) with similar baseline characteristics (average age: 46 years; 60% female). Cases versus controls had significantly more all-cause outpatient visits (incidence rate ratio [IRR], 95% confidence intervals [95% CI]: 1.64 [1.61, 1.67], P < .001) and all-cause hospitalizations (IRR [95% CI]: 1.92 [1.81, 2.04], P < .001); as well as significantly higher all-cause total direct healthcare costs (mean: $24 620 vs. $15 324; P < .001). Similar findings were observed for IBD-related outcomes, as well as in CD- and UC-specific subgroups.
Conclusions
Presence of fatigue is associated with an increase in HCRU and total medical costs among patients newly diagnosed with IBD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Massachusetts General Hospital and Harvard medical School, Boston, MA, USA.
- Department of Pharmaceutical Outcomes & Policy, University of Florida, Gainesville, FL, USA.
- Heath Economics and Outcomes Research, AbbVie Inc., North Chicago, ILUSA.
- Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
ORCID-Profile: Ashwin N Ananthakrishnan
Zitieren
APA
Ananthakrishnan, A. N., Desai, R., Lee, W. J., Griffith, J., Chen, N., & Loftus, E. V. (2023). Economic Burden of Fatigue in Inflammatory Bowel Disease. Crohn's & Colitis 360, 5(3). https://doi.org/10.1093/crocol/otad020
Vancouver
Ananthakrishnan AN, Desai R, Lee WJ, Griffith J, Chen N, Loftus EV. Economic Burden of Fatigue in Inflammatory Bowel Disease. Crohn's & Colitis 360. 2023;5(3). doi:10.1093/crocol/otad020
BibTeX
@article{Ananthakrishnan2023,
author = {Ananthakrishnan, Ashwin N and Desai, Raj and Lee, Wan-Ju and Griffith, Jenny and Chen, Naijun and Loftus, Edward V},
title = {Economic Burden of Fatigue in Inflammatory Bowel Disease},
journal = {Crohn's & Colitis 360},
year = {2023},
volume = {5},
number = {3},
doi = {10.1093/crocol/otad020}
}
EUVIMED